Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Report 2022 to 2030

Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis

$ 3999

Spain's Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market is expected to grow from $71 Mn in 2022 to $144 Mn in 2030 with a CAGR of 9.20% for the year 2022-30. There will certainly be more cases detected as PNH becomes more widely known among Spanish healthcare professionals and patients, which will raise the country's need for PNH therapies. The creation of novel PNH treatments with improved efficacy, including complement inhibitors, may boost demand and propel market expansion in Spain. The market is segmented by therapy, diagnostic test, by distribution channel. Some key players in this market include Almirall, Grifols, Faes Farma, Alnylam Pharmaceuticals, Amgen, CSL Behring and Bioverativ.

CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Jigyasu Bhandari

Buy Now

Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Executive Analysis

Spain's Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market size is at around $71 Mn in 2022 and is projected to reach $144 Mn in 2030, exhibiting a CAGR of 9.20% during the forecast period. In Spain, the annual cost of public healthcare is $96.46 billion, or $2,037.04 per resident. Prescription drug prices make up around 13.25 billion of those totals. The amount is increased by $34.72 billion (or $733.85 per resident) annually for commercial healthcare. As a result, the annual cost of Spain's healthcare system is $131.17 billion.

There are 1256 to 1368 people in Spain who have PNH. The lower end of the predicted range places the prevalence of PNH in Spain at about 1 per million individuals. Adults, who are typically between 35 and 40 years old, are more likely to be diagnosed with PNH. It has an equal influence on males and women. The blood condition known as Paroxysmal Nocturnal Hemoglobinuria (PNH) is uncommon and acquired. A PIGA gene mutation that results in a lack of certain proteins on the surface of red blood cells is what causes PNH. This deficiency can cause red blood cells to degrade early, which can cause a number of symptoms like exhaustion, breathlessness, and a higher risk of blood clots. Medications that can lessen red blood cell deterioration and prevent blood clots are frequently used to treat PNH. Eculizumab and eculizumab, both of which are permitted for use in the European Union, including Spain, may be among these drugs. Bone marrow transplantation may also be a possibility for treatment in some circumstances.

Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

There will certainly be more cases detected as PNH becomes more widely known among Spanish healthcare professionals and patients, which will raise the country's need for PNH therapies. The creation of novel PNH treatments with improved efficacy, including complement inhibitors, may boost demand and propel market expansion in Spain. Although PNH is a rare condition, more people are anticipated to develop it as a result of ageing populations and rising rates of PNH-related bone marrow abnormalities. In order to exchange knowledge, resources, and access to new markets and promote growth, manufacturers in the Spanish PNH pharmaceuticals market collaborate and form strategic alliances.

Market Restraints

Patients in Spain may find the expense of PNH therapies to be a substantial barrier, particularly those without insurance or with restricted coverage. This may reduce the demand for PNH treatments and have an impact on Spain's market expansion. Alternative treatments for PNH patients in Spain, like bone marrow transplantation or blood transfusions, may reduce the need for PNH medications in that country.

Competitive Landscape

Key Players

Almirall (ES)
Grifols (ES)
Faes Farma (ES)
Achillion Pharmaceuticals
Novartis International
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
Amgen
CSL Behring
Bioverativ

Healthcare Policies and Regulatory Landscape

The Spanish Agency for Medicines and Medical Devices (AEMPS) is one of the main regulatory organisations in charge of regulating the PNH market in Spain. Prior to issuing marketing permission, the AEMPS is in charge of assessing the efficacy, quality, and safety of pharmaceutical goods, including PNH therapies. The Spanish Ministry of Health, in addition to the AEMPS, is a key player in determining how healthcare policy will affect the PNH market. Setting reimbursement guidelines that specify which PNH treatments are paid for by the National Health System (SNS) and at what cost falls under the purview of the Ministry of Health. PNH therapies must go through a thorough evaluation procedure, including clinical trials and cost-effectiveness analyses, to be eligible for payment under the SNS. The Interministerial Commission for Prices of Medicines (CIPM), which regulates the process, establishes medicine prices in accordance with their value to patients and the healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Segmentation

By Therapy

Medication Therapy
Stem Cell Therapy
Blood Transfusion Therapy

By Diagnostic Tests

CBC
LHD
Bone Marrow Examination
Flow Cytometry

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.